Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma‐type post‐transplant lymphoproliferative disorder
- 18 February 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 189 (1), 97-105
- https://doi.org/10.1111/bjh.16304
Abstract
Post‐transplant lymphoproliferative disorder (PTLD) may arise after solid organ transplantation, and the most common subtype resembles diffuse large B cell lymphoma (DLBCL). In DLBCL‐type PTLD, the anti‐CD20 antibody rituximab (R) may be combined with chemotherapy (R‐CHOP) or use a strategy (R‐primary; similar to the PTLD‐1 clinical trial) consisting of induction with four weekly doses of R‐alone, without any chemotherapy or sequential R‐CHOP follow‐up. Here we report on a multicentre retrospective cohort of solid organ transplant patients with DLBCL‐type PTLD that were treated with R. In 168 adults, two‐year overall survival (OS) was 63·7% [95% CI (confidence interval) 56·6–71·7%]. No difference in OS was observed, whether patients were treated with R‐CHOP versus the R‐primary strategy. In the 109 patients treated with R‐primary, multivariate analysis found that baseline IPI score and the response to R‐induction predicted OS. Patients who responded to R‐induction had durable remissions without the addition of chemotherapy. Conversely, of the 46 patients who had stable or progressive disease after R‐induction (R‐failure), those who received R‐CHOP had an only marginally improved outcome, with a two‐year OS of 45% (23·1–65·3%) vs. no R‐CHOP at 32% (14·7–49·8%). In real‐world patients, R‐failure and high IPI scores predict a poor outcome in DLBCL‐type PTLD.Keywords
Funding Information
- Alberta Innovates Health Solutions
This publication has 16 references indexed in Scilit:
- Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2018
- Comprehensive review of post–organ transplant hematologic cancersAmerican Journal of Transplantation, 2018
- How I treat posttransplant lymphoproliferative disordersBlood, 2015
- The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative DisorderAmerican Journal of Transplantation, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factorsLeukemia & Lymphoma, 2013
- Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern EraJournal of Clinical Oncology, 2010
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantationHaematologica, 2007
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004